# Veru Inc (VERU) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/VERU
## Company Profile
- Ticker: VERU
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Oncology, Respiratory
## Stock Data
- Close: 2.33 USD
- Market cap: 37718252 USD
- Last updated: 2026-08-05
## Business Overview
### Cardiometabolic and Inflammation Company
Veru develops late-stage small molecules for cardiometabolic and inflammatory diseases.
### Enobosarm
Enobosarm is an oral selective androgen receptor modulator being evaluated to preserve lean mass, physical function, and bone health during GLP-1-driven weight loss in older adults with obesity.
### PLATEAU Study
The Phase 2b PLATEAU study combines enobosarm with semaglutide and measures body composition, weight, function, and safety.
## Why The Stock Is Moving

As of Aug 5, 2026, VERU closed down 1.69% at $2.33. No new same-company headline was identified in the current news window.

## Future Catalysts

- A PLATEAU interim analysis of lean and fat mass at 36 weeks is expected in the first quarter of 2027.
- Final topline PLATEAU data are expected in the fourth quarter of 2027.

## Drug Assets

- semaglutide

## Recent News
- 2026-08-04 12:30 EST — [Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss](https://biopharmsignal.com/news/VERU/veru-announces-notice-of-allowance-for-key-methods-of-use-u-s-patent-for-enobosa-a0328556) — Source: Veru Inc
- 2026-08-03 12:30 EST — [Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th](https://biopharmsignal.com/news/VERU/veru-to-report-fiscal-2026-third-quarter-financial-results-on-august-10th-3c5f1e88) — Source: Veru Inc
- 2026-07-30 12:30 EST — [Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference](https://biopharmsignal.com/news/VERU/veru-to-participate-in-fireside-chat-at-the-canaccord-genuity-s-46th-annual-grow-ba050a79) — Source: Veru Inc
- 2026-07-27 12:10 EST — [Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss](https://biopharmsignal.com/news/VERU/veru-announces-full-enrollment-for-phase-2b-plateau-clinical-trial-of-enobosarm--ce89119d) — Source: Veru Inc
- 2026-07-07 12:30 EST — [Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day](https://biopharmsignal.com/news/VERU/veru-to-present-at-2026-obesity-weight-loss-drug-development-summit-and-pre-conf-f5d70201) — Source: Veru Inc